Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MGLL | Q99685 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6236172 | 0.81 | HSD11B1 (1.00) | HSD11B1KDM4EPOLBGAAMGLL | |
| SCHEMBL6209947 | 0.77 | HSD11B1 (1.00) | HSD11B1KDM4EPOLBGAAMGLL | |
| SCHEMBL6209453 | 0.77 | SLC18A3 (0.75) | HSD11B1KDM4EPOLBGAAMGLL | |
| SCHEMBL19917560 | 0.76 | PRKAA2 (0.69) | HSD11B1POLBMGLLALDH1A1 | |
| SCHEMBL12184237 | 0.76 | CYP2C19 (0.70) | HSD11B1KDM4EPOLBGAAMGLL | |
| SCHEMBL1720014 | 0.76 | HSD11B1 (1.00) | HSD11B1KDM4EPOLBGAAMGLL | |
| SCHEMBL519021 | 0.75 | PRKAA2 (0.74) | — | |
| SCHEMBL6210205 | 0.75 | HSD11B1 (0.65) | HSD11B1KDM4EPOLBGAAMGLL | |
| SCHEMBL6212091 | 0.75 | MGLL (1.00) | HSD11B1KDM4EPOLBGAAMGLL | |
| SCHEMBL6210077 | 0.75 | HSD11B1 (0.86) | HSD11B1KDM4EPOLBGAAMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | HSD11B1 1963/4885KDM4E 926/4885POLB 2382/4885 |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | HSD11B1 1963/4885KDM4E 926/4885POLB 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.